Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs Indian Medical PG Practice Questions and MCQs

Question 301: Naloxone is the physiological antidote of which substance?

A. Alcohol
B. Cocaine
C. Barbiturates
D. Opium (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Opium** Naloxone is a **pure opioid antagonist** that acts by competitively binding to all three opioid receptors (μ, κ, and δ), with the highest affinity for the **mu (μ) receptor**. Opium and its derivatives (morphine, heroin, codeine) exert their effects by stimulating these receptors. Naloxone rapidly displaces opioids from the receptor sites, reversing life-threatening symptoms such as respiratory depression, sedation, and miosis. It is the drug of choice for acute opioid overdose. **Analysis of Incorrect Options:** * **A. Alcohol:** While Naltrexone (a long-acting antagonist) is used to reduce cravings in chronic alcoholism, Naloxone does not reverse acute ethanol toxicity, as alcohol acts primarily on GABA receptors. * **B. Cocaine:** Cocaine is a CNS stimulant that inhibits the reuptake of dopamine and norepinephrine. There is no specific pharmacological antagonist for cocaine; management is primarily supportive (e.g., benzodiazepines). * **C. Barbiturates:** These are GABA-A receptor modulators. There is no specific antidote for barbiturate poisoning; management involves gastric lavage and urinary alkalinization. (Note: Flumazenil is the antidote for Benzodiazepines, not Barbiturates). **High-Yield Clinical Pearls for NEET-PG:** * **Route & Duration:** Naloxone has a very short half-life (approx. 60–90 mins). Since many opioids (like Methadone) last longer, **repeated dosing or IV infusion** is often required to prevent "re-narcotization." * **Diagnostic Use:** It can be used in the "Naloxone Challenge Test" to identify opioid physical dependence. * **Acute Withdrawal:** Administration in a dependent individual will precipitate an immediate and severe **withdrawal syndrome** (rhinorrhea, lacrimation, pupillary dilation, and agitation).

Question 302: Colchicine is:

A. Analgesic
B. Anti-inflammatory
C. Uricosuric
D. None of the above (Correct Answer)

Explanation: ### Explanation **Why "None of the above" is the correct answer:** In the context of pharmacology and competitive exams like NEET-PG, **Colchicine** is classified specifically as an **Anti-mitotic** or **Anti-gout** agent. It does not possess intrinsic analgesic or anti-inflammatory properties in the traditional sense (like NSAIDs or Steroids). Its mechanism involves binding to **tubulin**, inhibiting its polymerization into microtubules. This disrupts the mobility and chemotaxis of neutrophils to the joint, preventing the release of inflammatory mediators. While this results in the resolution of a gouty attack, Colchicine itself is not an analgesic (it doesn't raise pain threshold) nor a general anti-inflammatory (it is ineffective in non-gouty inflammation like rheumatoid arthritis). **Analysis of Incorrect Options:** * **A. Analgesic:** Colchicine has no direct action on pain receptors or the central nervous system to alleviate pain. The pain relief in gout is a secondary consequence of stopping the inflammatory process. * **B. Anti-inflammatory:** It lacks a general anti-inflammatory effect. It is highly specific for gouty inflammation; it does not inhibit cyclooxygenase (COX) or phospholipase enzymes. * **C. Uricosuric:** Colchicine does not affect the renal excretion of uric acid (unlike Probenecid) nor does it inhibit uric acid synthesis (unlike Allopurinol). It has no effect on serum urate levels. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Colchicine is the drug of choice for **Prophylaxis** of gouty attacks and for **Familial Mediterranean Fever (FMF)**. * **Acute Gout:** While effective, NSAIDs are now preferred over Colchicine for acute attacks due to the latter's toxicity. * **Toxicity:** The most common early side effect is **diarrhea** (due to inhibition of mitosis in rapidly dividing gut replacement cells). * **Specific Side Effect:** Long-term use can lead to **myopathy** and **agranulocytosis**.

Question 303: Less gastrointestinal bleed is seen in the following NSAID.

A. Meloxicam
B. Naproxen
C. COX2 specific inhibitors (Correct Answer)
D. Ibuprofen

Explanation: The primary mechanism of NSAID-induced gastrointestinal (GI) toxicity is the inhibition of the **COX-1 enzyme**. COX-1 is constitutively expressed in the gastric mucosa, where it facilitates the synthesis of cytoprotective prostaglandins ($PGE_2$ and $PGI_2$) [3]. These prostaglandins increase bicarbonate secretion, enhance mucosal blood flow, and promote mucus production. **Why COX-2 Specific Inhibitors are correct:** COX-2 specific inhibitors (e.g., Celecoxib, Etoricoxib) selectively inhibit the inducible COX-2 enzyme responsible for inflammation and pain, while sparing the constitutive COX-1 enzyme in the stomach [1][2]. By preserving gastric prostaglandin synthesis, these drugs significantly reduce the risk of mucosal injury, peptic ulcers, and GI bleeding compared to non-selective NSAIDs [3]. **Analysis of Incorrect Options:** * **Meloxicam:** This is a *preferential* COX-2 inhibitor. While it has a higher affinity for COX-2, it still inhibits COX-1 to some degree, especially at higher doses, making it less GI-safe than "specific" inhibitors. * **Naproxen:** A non-selective NSAID with a relatively high risk of GI side effects [2]. It is often considered the most cardiosafe NSAID but requires co-administration with a Proton Pump Inhibitor (PPI) in high-risk patients. * **Ibuprofen:** A non-selective NSAID. While it has a lower GI risk profile compared to Aspirin or Indomethacin, it still inhibits COX-1 and carries a higher risk of GI bleed than specific COX-2 inhibitors [2]. **High-Yield Clinical Pearls for NEET-PG:** * **The "VIGOR" Trial:** Demonstrated that Rofecoxib had significantly fewer GI events than Naproxen. * **Cardiovascular Risk:** While COX-2 inhibitors are GI-friendly, they increase the risk of thrombotic events (MI/Stroke) because they inhibit $PGI_2$ (vasodilator/anti-aggregatory) without affecting Thromboxane $A_2$ (vasoconstrictor/pro-aggregatory) [1]. * **Drug of Choice:** For patients with a history of peptic ulcers requiring NSAIDs, a **COX-2 inhibitor + PPI** is the safest strategy.

Question 304: What is the DOC for acute attack of Hereditary angioneurotic edema?

A. Danazol
B. C1 inhibitor concentrate (Correct Answer)
C. Icatibant
D. Methylprednisolone

Explanation: **Explanation:** **Hereditary Angioneurotic Edema (HANE)** is caused by a deficiency or dysfunction of the **C1 esterase inhibitor**. This deficiency leads to the over-activation of the complement system and the kallikrein-kinin pathway, resulting in excessive production of **bradykinin**, which causes massive localized edema. **Why C1 Inhibitor Concentrate is the Correct Answer:** The Drug of Choice (DOC) for an acute attack is replacing the missing protein. **C1 inhibitor concentrate** (derived from human plasma or recombinant) directly addresses the underlying pathology by inhibiting the proteases that generate bradykinin, providing the most rapid and physiological resolution of the attack. **Analysis of Incorrect Options:** * **Danazol (Option A):** This is an attenuated androgen used for **prophylaxis** (prevention) of HANE. It works by increasing the hepatic synthesis of C1 inhibitor protein. It is ineffective in an acute attack because it takes days to increase protein levels. * **Icatibant (Option C):** This is a selective **Bradykinin B2 receptor antagonist**. While it is highly effective and used for acute attacks [2], current clinical guidelines (and NEET-PG standards) prioritize C1 inhibitor replacement as the primary DOC. *Note: Ecallantide (a kallikrein inhibitor) is another acute treatment option.* * **Methylprednisolone (Option D):** Corticosteroids and antihistamines are **ineffective** in HANE because the edema is mediated by bradykinin, not histamine or typical inflammatory leukotrienes [1]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Fresh Frozen Plasma (FFP):** Can be used in emergencies if C1 concentrate is unavailable, as it contains C1 inhibitor. 2. **Tranexamic Acid:** An antifibrinolytic sometimes used for prophylaxis if androgens are contraindicated. 3. **ACE Inhibitors:** These are strictly **contraindicated** in HANE patients because they prevent the breakdown of bradykinin, potentially triggering a life-threatening attack [2]. 4. **Clinical Presentation:** Recurrent episodes of non-pitting edema (skin, GI tract, or larynx) without urticaria or itching.

Question 305: Morphine is used in the treatment of which of the following conditions?

A. Hypertension
B. Cardiac arrhythmias
C. Acute left ventricular failure (Correct Answer)
D. A-V block

Explanation: **Explanation:** Morphine is a cornerstone in the management of **Acute Left Ventricular Failure (LVF)** and Acute Pulmonary Edema. Its therapeutic benefit is derived from its unique hemodynamic and central effects: 1. **Venodilation:** Morphine increases venous capacitance (peripheral pooling of blood), which reduces **preload**. This decreases the workload on the failing left ventricle. 2. **Arteriodilation:** It causes mild arterial dilation, reducing **afterload** and improving cardiac output. 3. **Anxiolysis:** By relieving the intense anxiety and "air hunger" (dyspnea) associated with pulmonary edema, it reduces sympathetic overactivity, further lowering myocardial oxygen demand. **Analysis of Incorrect Options:** * **A. Hypertension:** Morphine is not an antihypertensive. While it may cause a transient drop in BP due to histamine release and vasodilation, it is never used to treat chronic or acute hypertension. * **B. Cardiac Arrhythmias:** Morphine has no anti-arrhythmic properties. In fact, it can occasionally trigger bradycardia via vagal stimulation. * **D. A-V Block:** Morphine increases vagal tone, which can potentially worsen an atrioventricular (A-V) block. Atropine is the drug of choice for symptomatic bradycardia/A-V blocks. **NEET-PG High-Yield Pearls:** * **Mnemonic for LVF Management:** **LMNOP** (L-Loop diuretics, M-Morphine, N-Nitrates, O-Oxygen, P-Positioning/Pressors). * **Specific Antidote:** Naloxone is the competitive antagonist used for morphine overdose. * **Contraindications:** Avoid morphine in Head Injury (masks pupillary signs, increases ICP), Bronchial Asthma (histamine release), and Biliary Colic (causes spasm of the Sphincter of Oddi).

Question 306: Which drug is indicated for pain related to acute renal calculi?

A. Narcotic analgesics (Correct Answer)
B. Nonsteroidal anti-inflammatory drugs (NSAIDs)
C. Muscle relaxants
D. Salicylates

Explanation: **Explanation:** **1. Why Narcotic Analgesics are Correct:** Acute renal colic (caused by calculi) is characterized by sudden, excruciating pain that is often described as "crescendo-decrescendo" in nature. For the **immediate management of severe, acute pain**, narcotic analgesics (Opioids) like **Morphine, Pethidine, or Fentanyl** are considered the drugs of choice [1]. They act centrally on $\mu$-opioid receptors to provide rapid and potent analgesia [3]. While NSAIDs are excellent for reducing ureteral edema and prostaglandin-mediated pain, narcotics remain the gold standard for the initial "emergency" relief of high-intensity pain in a clinical setting [2]. **2. Why Other Options are Incorrect:** * **NSAIDs (e.g., Diclofenac):** While highly effective and often used in combination or for maintenance, they have a slower onset of action compared to IV narcotics [2]. In some guidelines, they are first-line for *moderate* pain, but for *acute, severe* episodes, narcotics are preferred. * **Muscle Relaxants:** These act on skeletal muscle and have no significant effect on the smooth muscle of the ureter. They do not provide adequate analgesia for renal colic. * **Salicylates (Aspirin):** These are relatively weak analgesics for visceral pain and carry a risk of antiplatelet effects, which is undesirable if the patient requires urgent surgical intervention (e.g., lithotripsy or stenting). **3. NEET-PG High-Yield Pearls:** * **Pethidine (Meperidine)** was historically preferred over Morphine because it was thought to cause less spasm of the Sphincter of Oddi/ureter, though recent evidence suggests little clinical difference [1]. * **NSAIDs** work by inhibiting Prostaglandin synthesis, which reduces renal blood flow and pelvic pressure, addressing the *cause* of the pain. * **Combination Therapy:** The most effective clinical approach is often a combination of an NSAID (for inflammation/pressure) and an Opioid (for immediate pain perception).

Question 307: What is the best drug for acute gout in a patient with renal impairment?

A. Naproxen (Correct Answer)
B. Probenecid
C. Allopurinol
D. Sulfinpyrazone

Explanation: **Explanation:** The management of acute gout focuses on rapid pain relief and inflammation control. The first-line agents are **NSAIDs**, Colchicine, or Glucocorticoids. **Why Naproxen is correct:** Among the options provided, **Naproxen** (an NSAID) is the drug of choice for an acute attack. While all NSAIDs must be used with caution in renal impairment, they remain the standard for acute symptom control. However, in clinical practice, if renal impairment is severe (CrCl <30 ml/min), NSAIDs are generally avoided in favor of systemic or intra-articular corticosteroids. In the context of this specific MCQ, Naproxen is the only agent listed that treats the *acute* inflammatory phase. **Why the other options are incorrect:** * **Probenecid & Sulfinpyrazone:** These are **uricosuric drugs**. They are used for *chronic* gout (intercritical period) to lower uric acid levels. They are ineffective during an acute attack and are actually contraindicated in patients with renal impairment/urolithiasis as they increase the risk of uric acid stones. * **Allopurinol:** This is a **Xanthine Oxidase Inhibitor** used for *chronic* prophylaxis. Starting Allopurinol during an acute attack is contraindicated as it can fluctuate serum urate levels, potentially worsening or prolonging the acute episode. **High-Yield NEET-PG Pearls:** 1. **Drug of Choice (DOC) for Acute Gout:** NSAIDs (e.g., Indomethacin, Naproxen). 2. **DOC for Acute Gout with Renal Failure:** Corticosteroids (Prednisolone) are preferred over NSAIDs and Colchicine. 3. **Colchicine Toxicity:** Limited by GI side effects (diarrhea). It inhibits microtubule polymerization by binding to tubulin. 4. **Allopurinol Caution:** Always co-administer with low-dose NSAIDs or Colchicine when starting Allopurinol to prevent "mobilization flares."

Question 308: Abatacept is:

A. TNF alpha inhibitor
B. Inhibitor of co-stimulation of T cells (Correct Answer)
C. IL-1 receptor antagonist
D. Monoclonal antibody against IL-6 receptor

Explanation: **Explanation:** **Mechanism of Action (Why B is correct):** Abatacept is a soluble fusion protein consisting of the extracellular domain of human **CTLA-4** linked to the modified Fc portion of human IgG1. It acts as a **selective co-stimulation modulator**. For a T-cell to become fully activated, it requires two signals: 1. The binding of the T-cell receptor to the Antigen-MHC complex. 2. A **co-stimulatory signal** involving the binding of **CD80/CD86** on antigen-presenting cells (APCs) to **CD28** on T-cells. Abatacept binds to CD80 and CD86 with high affinity, preventing them from binding to CD28, thereby inhibiting T-cell activation and the subsequent inflammatory cascade in Rheumatoid Arthritis. **Analysis of Incorrect Options:** * **Option A (TNF-α inhibitors):** These include drugs like **Etanercept** (soluble receptor), **Infliximab**, and **Adalimumab** (monoclonal antibodies). They target the cytokine TNF-α directly. * **Option C (IL-1 receptor antagonist):** This refers to **Anakinra**, which competitively inhibits the binding of IL-1 to its receptor. * **Option D (Anti-IL-6 receptor antibody):** This refers to **Tocilizumab** and **Sarilumab**, which block IL-6 signaling. **High-Yield Clinical Pearls for NEET-PG:** * **Belatacept:** A related drug (modified version of Abatacept) used primarily in **renal transplantation** to prevent graft rejection. * **Indication:** Abatacept is used in patients with moderate-to-severe Rheumatoid Arthritis who have had an inadequate response to DMARDs (like Methotrexate) or TNF inhibitors. * **Contraindication:** It should **not** be used concurrently with TNF-α inhibitors due to an increased risk of serious infections.

Question 309: Which of the following drugs is a selective COX-2 inhibitor?

A. Ketorolac
B. Etoricoxib (Correct Answer)
C. Piroxicam
D. Nimesulide

Explanation: **Explanation:** The correct answer is **Etoricoxib**. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are classified based on their selectivity for the Cyclooxygenase (COX) enzymes. COX-1 is constitutive (protective for gastric mucosa and platelets), while COX-2 is inducible (mediated by inflammation). **Etoricoxib** belongs to the "coxib" class, which are **highly selective COX-2 inhibitors**. These drugs provide potent anti-inflammatory and analgesic effects with a significantly lower risk of gastrointestinal ulcers and bleeding compared to non-selective agents. **Analysis of Incorrect Options:** * **A. Ketorolac:** A potent non-selective NSAID with a high affinity for **COX-1**. It is primarily used for short-term management of severe acute pain but carries a high risk of GI toxicity. * **C. Piroxicam:** An oxicam derivative that is a **non-selective** COX inhibitor with a long half-life. It is associated with a higher incidence of gastric side effects. * **D. Nimesulide:** Classified as a **preferential** COX-2 inhibitor (not highly selective). While it favors COX-2, it still inhibits COX-1 to some degree. **High-Yield Clinical Pearls for NEET-PG:** * **Selectivity Ratio:** Etoricoxib has the highest COX-2 selectivity among the available coxibs (Etoricoxib > Valdecoxib > Celecoxib). * **Cardiovascular Risk:** Selective COX-2 inhibitors lack anti-platelet activity (as they don't inhibit TXA2) and may shift the balance toward pro-thrombotic states, increasing the risk of myocardial infarction and stroke. * **Sulfonamide Allergy:** Celecoxib contains a sulfonamide moiety; use with caution in patients with sulfa allergies. * **Aspirin-Exacerbated Respiratory Disease (AERD):** Selective COX-2 inhibitors are generally safe in patients with "Aspirin Triad" (asthma, nasal polyps, and NSAID sensitivity).

Question 310: Which of the following is a disease-modifying antirheumatic drug (DMARD)?

A. Desferrioxamine
B. Penicillamine (Correct Answer)
C. Succimer
D. Dimercaprol

Explanation: ### Explanation **Correct Answer: B. Penicillamine** **Concept:** Disease-modifying antirheumatic drugs (DMARDs) are a category of drugs used in Rheumatoid Arthritis (RA) that do not just provide symptomatic relief (unlike NSAIDs) but actually slow down disease progression and prevent joint destruction. **Penicillamine** is a chelating agent that also possesses immunosuppressive properties. It reduces the numbers of T-lymphocytes, inhibits macrophage function, and decreases IL-1 and rheumatoid factor titers. While it was historically a mainstay in RA treatment, its use has significantly declined due to a high incidence of toxicity (e.g., proteinuria, bone marrow suppression, and drug-induced lupus). **Analysis of Incorrect Options:** * **A. Desferrioxamine:** This is a specific chelating agent used for **acute iron poisoning** and chronic iron overload (hemosiderosis/hemochromatosis). It has no role in modifying rheumatic disease. * **C. Succimer (DMSA):** This is a water-soluble analog of dimercaprol used primarily for **lead poisoning** in children and mercury/arsenic poisoning. * **D. Dimercaprol (BAL):** This is a chelating agent used for **arsenic, mercury, and gold poisoning**. It is administered intramuscularly and is contraindicated in iron or cadmium poisoning as the resulting complexes are nephrotoxic. **High-Yield Clinical Pearls for NEET-PG:** * **Classification of DMARDs:** Divided into **Synthetic** (Methotrexate—the "Gold Standard" and first-line; Sulfasalazine, Leflunomide, Hydroxychloroquine) and **Biological** (TNF-α inhibitors like Etanercept, Infliximab; IL-1 receptor antagonists like Anakinra). * **Penicillamine Dual Role:** Remember it as a "Bridge" drug—it is the drug of choice for **Wilson’s Disease** (copper chelation) and a second-line DMARD for RA. * **Side Effect Profile:** Penicillamine is notorious for causing **membranous glomerulonephritis** and **myasthenia gravis-like syndrome**. Always monitor for proteinuria.

Practice by Chapter

NSAIDs: Classification and Mechanism

Practice Questions

COX-2 Selective Inhibitors

Practice Questions

Acetaminophen (Paracetamol)

Practice Questions

Opioid Analgesics and Antagonists

Practice Questions

Drugs Used in Gout and Hyperuricemia

Practice Questions

Drugs Used in Rheumatoid Arthritis

Practice Questions

Disease-Modifying Antirheumatic Drugs

Practice Questions

Glucocorticoids as Anti-inflammatory Agents

Practice Questions

Migraine Therapeutics

Practice Questions

Neuropathic Pain Management

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free